Navigation Links
Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
Date:2/29/2008

16 29

Deferred revenue 228 228

Accrued severance pay 324 344

Total Long-term Liabilities 568 601

COMMITMENTS AND CONTINGENT LIABILITIES

SHAREHOLDERS' EQUITY:

Share capital: 27 17

Additional paid-in capital 58,984 31,958

Other comprehensive income 86 3

Deferred stock-based compensation - (48)

Deficit accumulated during the

development stage (35,492) (20,831)

Total shareholders' equity 23,605 11,099

Total liabilities and shareholders'

equity 26,038 $ 13,243

[1] Avastin is a registered trademark of Genentech, Inc.

Contact: Media

Rachel Spielman

T: +1-212-583-2714

E: media@rosettagenomics.com

Investors

Ron Kamienchick

T: +1-646-509-1893

E: investors@rosettagenomics.com


'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Rosetta Genomics Establishes Medical Advisory Board
2. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
3. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
4. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
5. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
6. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
7. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
8. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
11. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Topical BioMedics, Inc., is ... pain end their suffering, restoring hope an quality of ... is only possible because of the innovative cellular biomedicines ... technology a reality. , The company was founded ... Lou Paradise (president, chief of research, and Topricin inventor), ...
(Date:9/22/2014)... TORONTO , Sept. 22, 2014 ... announced that it has entered into a collaboration ... UHN,s Centre for Molecular Design and Preformulations (CMDP) ... The goal of the project is to increase ... proprietary buccal insulin spray product, thereby reducing the ...
(Date:9/22/2014)... Norway (PRWEB) September 22, 2014 ... new parcel and pallet measuring device CNS110 ... eliminates manual data entry, offering greater ease and ... savings that result can significantly enhance productivity—an important ... industries where processing volume equals profits. , ...
(Date:9/21/2014)... 21, 2014 Chemical Sciences play ... such as clean air and safe water, healthy ... products. Chemists, environmentalists, food scientists, educators, and scientists ... in the field of Chemistry for the national ... is one of the fastest emerging Sciences, accelerating ...
Breaking Biology Technology:Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4ScanTape™ Handheld Dimensioner Increases Processing Volume 2Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3
... Results for Sponsoring BrandsCINCINNATI, May 12 ... of physician office-based patient-education programs, announces another record ... climate, the company continued to experience double-digit growth, ... primary care programs (a digital screen waiting room ...
... May 12 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... BioMarin, will present a company update at the Deutsche Bank ... 19, 2009 at 1:55 p.m. ET. Interested parties may ... the investor section of the BioMarin website, www.BMRN.com ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... has successfully completed patient enrolment in its multi-centre Phase ... REOLYSIN(R) in patients with various sarcomas that have metastasized ... been enrolled in the trial. , "We are extremely ...
Cached Biology Technology:Healthy Advice Networks Achieves Strong Growth Despite Challenging Economy 2BioMarin to Present at the Deutsche Bank Health Care Conference 2Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study 2Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study 3
(Date:9/22/2014)... 2014) Additive manufacturing (AM), or 3D printing, ... of complex-shaped metal components strong enough for structural ... and distortions, as well as quality standards to ... with the technology. Engineers at the University of ... develop enhanced modeling and simulation (M&S) technology and ...
(Date:9/22/2014)... SHELTON, Conn. , Sept. 22, 2014 ... authentication company focused on the growing mobile commerce market, ... to NASDAQ and the recent funding. ... recently completed an essential round of funding and joined ... as well as expand its other biometric and authentication ...
(Date:9/21/2014)... are set to rise again in 2014 - reaching a ... cent projected rise in burning fossil fuels is revealed by ... by researchers at the Tyndall Centre for Climate Change Research ... Engineering, Mathematics and Physical Sciences at the University of Exeter. ... where world leaders will seek to catalyse action on climate ...
Breaking Biology News(10 mins):Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3
... international research consortium has sequenced the genome of the ... Dec. 26 advance online edition of the journal ... possibilities for breeding tastier, hardier varieties of the berry ... the strawberry parts list," said the consortium,s leader Kevin ...
... COLLEGE PARK, Md. The latest success of Martek ... a decade ago in a plain, brick building on ... and early-stage nurturing from the university,s Maryland Technology Enterprise ... into a major international business. On December ...
... University of Arizona researchers may have found a way ... doses without harming healthy body cells. If successful, ... effective to destroy cancer cells and alleviate the harmful ... The invention by Marek Romanowski, an associate professor of ...
Cached Biology News:Georgia Tech team helps decode newly sequenced strawberry genome 2Georgia Tech team helps decode newly sequenced strawberry genome 3Tech firm joins the 'billion dollar club' -- with university help 2Tech firm joins the 'billion dollar club' -- with university help 3Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy 2Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy 3Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy 4
... kit I provides reagents and a protein standard ... reducing agents and detergents. The RC DC protein ... reagents and standards sufficient for 500 standard assays: ... reagent II, 250 ml alkaline copper tartrate solution, ...
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
... The Eclipse is a state-of-the-art separation ... Fractionation (AFFF) technique. The Eclipse integrates easily ... DAWN, miniDAWN Tristar, as well as the ... size and molar mass distributions of the ...
... reagent kit for determining the absolute count ... samples, mobilized peripheral blood samples, and leukapheresis ... total nucleated cell count and a total ... designed for use in the BD Procount ...
Biology Products: